Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 2/20 | 0.32 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
| ▸ | CCR8 | P51685 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.31 |
| ▸ | DRD1 | P21728 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18238715 | 0.75 | BRD4 (0.32) | BRD4 | |
| SCHEMBL29954559 | 0.72 | CCR1 (0.34) | CCR1CCR5CCR8 | |
| SCHEMBL3543229 | 0.72 | — | — | |
| SCHEMBL2996456 | 0.72 | COMT (0.32) | KDM4E | |
| SCHEMBL10293735 | 0.71 | EPHX2 (0.43) | BRD4CYP1A2CYP3A4HSD17B10CYP2C9 | |
| SCHEMBL17537338 | 0.71 | CYP2A6 (0.41) | CYP2A6CYP1A2CYP3A4HSD17B10CYP2C9 | |
| SCHEMBL2757287 | 0.70 | HTR2C (0.47) | CYP2A6PDE3BPDE3ADRD1 | |
| SCHEMBL12266516 | 0.69 | CYP2A6 (0.56) | CYP2A6PDE3BPDE3AL3MBTL1CYP1A2 | |
| SCHEMBL14691409 | 0.68 | KMT2A (0.33) | BRD4POLBUSP2ALDH1A1KDM4E | |
| SCHEMBL8404485 | 0.68 | CCR1 (0.35) | CYP2A6BRD4CYP1A2CCR1CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11505541-B2 | Protein kinase C inhibitors and methods of their use | NOVARTIS AG (CH) | 2022-11-22 | — | — | US | disclosed |
| US-20210387962-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2021-12-16 | — | — | US | disclosed |
| US-11059804-B2 | Protein kinase C inhibitors and methods of their use | NOVARTIS AG (CH) | 2021-07-13 | — | — | US | disclosed |
| EP-3177608-B1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2019-09-18 | — | — | EP | disclosed |
| EP-3514151-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | Novartis AG (CH) | 2019-07-24 | — | — | EP | disclosed |
| US-9845309-B2 | Protein kinase C inhibitors and methods of their use | NOVARTIS AG (CH) | 2017-12-19 | — | — | US | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| US-20160347737-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2016-12-01 | — | — | US | disclosed |
| US-9452998-B2 | Protein kinase C inhibitors and methods of their use | NOVARTIS AG (CH) | 2016-09-27 | — | — | US | disclosed |
| US-20160046605-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2016-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | CYP2A6 2675/4885PDE3B 4693/4885PDE3A 4572/4885 |
| US-20210387962-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | PRKCA, PRKCB, PRKCH | CYP2A6 3008/4885PDE3B 518/4885PDE3A 470/4885 |
| US-11505541-B2 | Protein kinase C inhibitors and methods of their use | PRKCA, PRKCB, PRKCH | CYP2A6 3008/4885PDE3B 518/4885PDE3A 470/4885 |
| US-20160046605-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | PRKCA, PRKCB, PRKCH | CYP2A6 3008/4885PDE3B 518/4885PDE3A 470/4885 |
| US-11059804-B2 | Protein kinase C inhibitors and methods of their use | PRKCA, PRKCB, PRKCH | CYP2A6 3008/4885PDE3B 518/4885PDE3A 470/4885 |
| US-20160347737-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | PRKCA, PRKCB, PRKCH | CYP2A6 3008/4885PDE3B 518/4885PDE3A 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.